Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

MERCK KGAA : Kepler Cheuvreux remains its Buy rating

10/28/2020 | 12:11pm EST

Kepler Cheuvreux analyst David Evans maintains his Buy rating on the stock. The target price is revised upwards from EUR 144 to EUR 134.


© MarketScreener with dpa-AFX Analyser 2020
All news about MERCK KGAA
11/26MERCK : Partners With Siemens on New Plant
DJ
11/24Deutsche Bank's Depositary Receipts Virtual Investor Conference presentations..
AQ
11/24MERCK KGAA : Correction of a release from 25/03/2020 according to Article 40, Se..
EQ
11/23MERCK : Massachusetts-based Businesses of Merck KGaA, Darmstadt, Germany named t..
AQ
11/23MERCK KGAA : Release according to Article 40, Section 1 of the WpHG [the German ..
EQ
11/19MERCK : EMD Serono's Embracing Carers Announces Study Results on COVID-19 and Ca..
AQ
11/17MERCK KGAA : UBS reiterates its Neutral rating
MD
11/16MERCK KGAA : Goldman Sachs keeps a Sell rating
MD
11/16MERCK KGAA : JP Morgan remains Neutral
MD
11/13MERCK KGAA : Deutsche Bank keeps its Buy rating
MD
More news
Financials
Sales 2020 17 381 M 20 829 M 20 829 M
Net income 2020 2 013 M 2 412 M 2 412 M
Net Debt 2020 11 224 M 13 451 M 13 451 M
P/E ratio 2020 28,6x
Yield 2020 1,06%
Capitalization 57 999 M 69 344 M 69 507 M
EV / Sales 2020 3,98x
EV / Sales 2021 3,70x
Nbr of Employees 58 077
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 135,37 €
Last Close Price 133,40 €
Spread / Highest target 26,7%
Spread / Average Target 1,48%
Spread / Lowest Target -24,3%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA26.63%69 344
INDIVIOR155.77%975
KNIGHT THERAPEUTICS INC.-27.18%554
MAYNE PHARMA GROUP LIMITED-17.24%441
CORMEDIX INC.23.08%288
ISOFOL MEDICAL AB (PUBL)-18.32%170